URGN Projected Dividend Yield
Ord/UroGen Pharma Ltd ( NASDAQ : URGN )UroGen Pharma is a biotechnology company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co. has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Co.'s Jelmyto® (mitomycin) for pyelocalyceal solution, and its UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively. 20 YEAR PERFORMANCE RESULTS |
URGN Dividend History Detail URGN Dividend News URGN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |